Show simple item record

dc.contributor.authorCosta, Luis
dc.contributor.authorBadia, Xavier
dc.contributor.authorChow, Edward
dc.contributor.authorLipton, Allan
dc.contributor.authorWardley, Andrew M
dc.date.accessioned2009-04-01T23:16:54Z
dc.date.available2009-04-01T23:16:54Z
dc.date.issued2008-08
dc.identifier.citationImpact of skeletal complications on patients' quality of life, mobility, and functional independence. 2008, 16 (8):879-89 Support Care Canceren
dc.identifier.issn0941-4355
dc.identifier.pmid18392862
dc.identifier.doi10.1007/s00520-008-0418-0
dc.identifier.urihttp://hdl.handle.net/10541/58692
dc.description.abstractINTRODUCTION: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. DISCUSSION: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.
dc.language.isoenen
dc.subjectBone Metastasesen
dc.subjectBone Painen
dc.subjectBreast Canceren
dc.subjectProstate Canceren
dc.subjectZoledronic Aciden
dc.subject.meshBone Density Conservation Agents
dc.subject.meshBone Neoplasms
dc.subject.meshBreast Neoplasms
dc.subject.meshDiphosphonates
dc.subject.meshFemale
dc.subject.meshFractures, Bone
dc.subject.meshHealth Status
dc.subject.meshHumans
dc.subject.meshImidazoles
dc.subject.meshMale
dc.subject.meshPain
dc.subject.meshProstatic Neoplasms
dc.subject.meshQuality of Life
dc.titleImpact of skeletal complications on patients' quality of life, mobility, and functional independence.en
dc.typeArticleen
dc.contributor.departmentInstituto de Medicina Molecular-Lisboa, Servico de Oncologia, Hospital de Santa Maria, Av Professor Egaz Moniz, Lisbon, 1649-039, Portugal. luiscosta.p@netcabo.pten
dc.identifier.journalSupportive Care in Canceren
html.description.abstractINTRODUCTION: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life. DISCUSSION: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.


This item appears in the following Collection(s)

Show simple item record